Anti-TNFalpha drugs are currently used in the treatment of patients with Crohn's disease. Studies have reported neurological side effects occurring after anti-TNFalpha treatment, including infliximab-induced complications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00042737-200605000-00021 | DOI Listing |
Intern Med J
January 2025
Crohn's Colitis Cure, Sydney, New South Wales, Australia.
Background: The burden of inflammatory bowel disease (IBD) is often reported on from a system or cost viewpoint. We created and explored a novel patient-perceived burden of disease (PPBoD) score in a large Australasian cohort.
Aim: To create and explore a novel patient-perceived burden of disease (PPBoD) score in a large Australasian cohort, and correlate PPBoD scores with demographics, disease and treatment factors.
Am J Case Rep
January 2025
Department of Surgery, Cantonal Hospital of Fribourg (HFR), Villars-sur-Glâne, Switzerland.
BACKGROUND Crohn disease is a chronic inflammatory bowel disease known for causing fistulous tracts, abscesses, and bowel perforation. Enterohepatic fistulas, a rare but significant complication, are scarcely reported. This article presents the case of a hepatic abscess due to an enterohepatic fistula in a patient with long-term Crohn disease and reviews the existing literature on this phenomenon.
View Article and Find Full Text PDFColorectal Dis
January 2025
Division of Colon and Rectal Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Aim: Crohn's disease (CD) is regarded as a wasting disease, yet there is a growing population of CD patients with a body mass index (BMI) of 35 and above. The rate of postoperative complications is relatively high in CD patients but might be even higher in CD with morbid obesity (MO).
Methods: This was a retrospective study using a prospectively maintained database of all patients undergoing Ileocolic resection for CD between 2014 and 2021 in two referral centres, comparing postoperative complication rates according to BMI.
Aliment Pharmacol Ther
January 2025
Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo, Japan.
Aliment Pharmacol Ther
January 2025
Department of Medicine, University of Otago, Christchurch, New Zealand.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!